Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 12/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714717 | 0.87 | HTR3A (0.47) | HTR3ASLC6A5MAOAMAOBMCHR1 | |
| SCHEMBL30714742 | 0.86 | SLC6A5 (0.40) | HTR3ASLC6A5 | |
| SCHEMBL30714614 | 0.84 | GUCY1B2 (0.40) | HTR3ASLC6A5 | |
| SCHEMBL30714550 | 0.83 | KDM4E (0.46) | HTR3ASLC6A5 | |
| SCHEMBL30714709 | 0.83 | SSTR4 (0.43) | SLC6A5 | |
| SCHEMBL30714657 | 0.82 | SLC6A5 (0.43) | HTR3ASLC6A5 | |
| SCHEMBL30714707 | 0.81 | HTR3A (0.44) | HTR3A | |
| SCHEMBL30714676 | 0.80 | APOL1 (0.49) | HTR3AMAOAMAOBMCHR1 | |
| SCHEMBL30714565 | 0.80 | HTR3A (0.44) | HTR3AMAOAMAOBMCHR1 | |
| SCHEMBL30714693 | 0.79 | HTR3A (0.47) | HTR3AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | HTR3A 62/4885SLC6A5 904/4885MAOA 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.